OVCON-50
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OVCON-50 (OVCON-50).
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation, and alters cervical mucus and endometrial lining.
| Metabolism | Hepatic; ethinyl estradiol via CYP3A4; norethindrone via reduction and conjugation. |
| Excretion | Renal: 40-60% (metabolites, primarily glucuronide conjugates; <1% unchanged). Fecal: 30-50% (via biliary elimination). |
| Half-life | Norethindrone: 5-14 hours (terminal); ethinyl estradiol: 7-20 hours. Clinical context: Steady-state reached within 5-7 days; half-life allows once-daily dosing with stable contraceptive efficacy. |
| Protein binding | Norethindrone: 95-97% (mainly albumin, 35% SHBG); ethinyl estradiol: 97-99% (mainly albumin). |
| Volume of Distribution | Norethindrone: 2-4 L/kg; ethinyl estradiol: 1.5-3 L/kg. Indicates extensive tissue distribution, including breast, uterus, and hypothalamus. |
| Bioavailability | Oral: Norethindrone 60-70%; ethinyl estradiol 40-50% (first-pass metabolism; CYP3A4 and conjugation). |
| Onset of Action | Oral: 7 days of consecutive dosing required for full contraceptive effect; immediate if started within first 5 days of menstrual cycle. |
| Duration of Action | 24 hours (supports once-daily dosing). Missed dose guidelines apply beyond 24 hours; contraceptive failure risk increases with extended noncompliance. |
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg) orally once daily for 21 days followed by 7 days of placebo or no tablets.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Limited data in severe impairment; use with caution and monitor for fluid retention. |
| Liver impairment | Contraindicated in Child-Pugh class B and C (severe hepatic impairment). Use with caution in class A; consider alternative therapy due to potential metabolic impairment. |
| Pediatric use | Not indicated for use before menarche. Post-menarche: same adult dosing (one tablet daily). |
| Geriatric use | Not indicated for postmenopausal women; if used, consider increased risk of thromboembolic events and cardiovascular disease. No specific dose adjustment, but use lowest effective dose if necessary. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OVCON-50 (OVCON-50).
| Breastfeeding | Contraindicated in breastfeeding. Combined oral contraceptives reduce milk production and composition. Small amounts of estrogen and progestin transfer to breast milk; M/P ratio not established. Avoid use until weaning. |
| Teratogenic Risk | Pregnancy Category X. First trimester: Use contraindicated due to risk of congenital anomalies, including cardiovascular and limb defects. Second and third trimesters: Associated with fetal harm (e.g., genital abnormalities in females, feminization of male fetuses) and increased risk of fetal loss. Contraindicated throughout pregnancy. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events; contraindicated in women over 35 who smoke.
| Serious Effects |
["Thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected pregnancy","Undiagnosed abnormal genital bleeding","Known or suspected breast cancer","Hepatic adenoma or carcinoma","Hypersensitivity to components","Smoking in women over 35"]
| Precautions | ["Increased risk of thromboembolic disorders","Cardiovascular disease risk in smokers","Hepatic neoplasia","Gallbladder disease","Hypertension"] |
Loading safety data…
| Fetal Monitoring |
| Monitor for pregnancy status (rule out pregnancy before initiation). If inadvertent exposure occurs, monitor fetal development via ultrasound. Assess for thromboembolic events in mother. No routine fetal monitoring required if contraindicated. |
| Fertility Effects | Reversible suppression of ovulation. After discontinuation, fertility typically returns within 1-3 cycles. No permanent negative impact on fertility. |